

Subject Step Therapy Prohibition for Metastatic Cancer

Authors Cantrell and others

Analyst Randall Chun

Date March 29, 2019

## Overview

This bill prohibits the use of step therapy protocols when treating stage four advanced metastatic cancer, if the drug to be used for treatment meets specified criteria.

## Summary

Section	Description
1	<p><b>Prohibition on use of step therapy for metastatic cancer.</b> Adds § 62Q.1841.</p> <p><b>Subd. 1. Definitions.</b> Defines the following terms: health plan, stage four metastatic cancer, and step therapy protocol.</p> <p><b>Subd. 2. Prohibition on use of step therapy protocols.</b> Prohibits a health plan that provides coverage for the treatment of stage four advanced metastatic cancer or associated conditions from limiting or excluding coverage for a drug approved by the Food and Drug Administration (FDA) that is on the plan's formulary, by mandating that the enrollees follow a step therapy protocol, if the use of the approved drug is consistent with: (1) a FDA-approved indication; and (2) a clinical practice guideline published by the National Comprehensive Care Network.</p> <p>States that the section is effective January 1, 2020, and applies to health plans offered, issued, or renewed on or after that date.</p>
2	<p><b>Prior authorization.</b> Amends § 256B.0625, subd. 13f. Requires any step therapy protocol requirements established by the Commissioner of Human Services to comply with section 62Q.1841. Provides a January 1, 2020, effective date.</p>



**MN HOUSE  
RESEARCH**

*Minnesota House Research Department provides nonpartisan legislative, legal, and information services to the Minnesota House of Representatives. This document can be made available in alternative formats.*

[www.house.mn/hrd](http://www.house.mn/hrd) | 651-296-6753 | 600 State Office Building | St. Paul, MN 55155